AtriCure vs Bioventus
ATRC and BVS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRC and BVS compare
AtriCure is the larger company, worth 3.2 times as much as Bioventus ($2.9B against $924M).
On earnings, Bioventus is cheaper: it trades at 13.7× trailing earnings, against 192× for AtriCure.
AtriCure grew revenue faster over the last twelve months (13.8% versus 3.9% for Bioventus).
Bioventus keeps more of each dollar of sales as profit, with a net margin of 9.8% compared with 2.5% at AtriCure.
Bioventus scores higher on the StockData Score (14 against 12 for AtriCure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRC | BVS |
|---|---|---|
| Size and price | ||
| Market cap | $2.9B | $924M |
| Share price | $57.53 | $10.99 |
| Change, 1 year | 79.8% | 46.7% |
| Change, 5 years | −25.9% | −21.6% |
| Beta (5Y) | 1.26 | 0.91 |
| Employees | 1,350 | 930 |
| StockData Score | ||
| Total score | 12 | 14 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 4 (better) | 3 |
| Performance score | 3 | 5 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 192× | 13.7× (better) |
| P/S | 5.0× | 1.6× (better) |
| P/B | 5.5× | 3.8× (better) |
| EV/EBITDA | 164× | 14.4× (better) |
| P/FCF | 55.3× | 10.9× (better) |
| FCF yield | 1.8% | 9.2% (better) |
| Fair value | $8.19 | $16.36 |
| Margin of safety | −603% | 32.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.8% (better) | 3.9% |
| Revenue growth, 5Y average | 20.9% (better) | 12.1% |
| Net income growth (TTM) | – | 655% |
| EPS growth (TTM) | – | 627% |
| Profitability | ||
| Gross margin | 76.7% (better) | 68.7% |
| Operating margin | 2.9% | 9.7% (better) |
| Net margin | 2.5% | 9.8% (better) |
| FCF margin | 9.0% | 14.5% (better) |
| Return on equity | 2.9% | 28.2% (better) |
| Return on invested capital | 3.9% | 12.8% (better) |
| Financial health | ||
| Debt / equity | 0.11 (better) | 0.96 |
| Net debt / EBITDA | −7.40 | 2.44 (better) |
| Interest coverage | 2.9× | – |
| Current ratio | 4.33 (better) | 1.68 |
| Altman Z-score | 10.11 (better) | 2.19 |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.31% |
| Shareholder yield | 0.00% (better) | −0.31% |
| Ownership | ||
| Held by institutions | 104% | 71.2% |
| Held by insiders | 4.0% | 29.0% |
| Insider net buying, 12 months | −$4.4M | −$181K (better) |
| Short interest, % of float | 10.0% | 5.1% |
Go deeper
- ATRC stock overview
- ATRC income statement
- ATRC valuation and score
- BVS stock overview
- BVS income statement
- BVS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.